Robotic, Laparoscopic Surgery Compared in Endometrial Cancer

Publication
Article
OncologyONCOLOGY Vol 23 No 3
Volume 23
Issue 3

Patients with endometrial cancer who have minimally invasive robotic-assisted hysterectomies tend to have quicker surgeries and shorter hospital stays compared with patients who have similar laparoscopic surgical procedures, according to new research from The Ohio State University Comprehensive Cancer–James Cancer Hospital and Solove Research Institute.

Patients with endometrial cancer who have minimally invasive robotic-assisted hysterectomies tend to have quicker surgeries and shorter hospital stays compared with patients who have similar laparoscopic surgical procedures, according to new research from The Ohio State University Comprehensive Cancer–James Cancer Hospital and Solove Research Institute.

Until now, little data existed to confirm the benefit of minimally invasive robotic-assisted surgery for patients with endometrial cancer. The findings are published online in the journal Gynecologic Oncology, and were also presented during a national meeting of the Society of Gynecologic Oncologists, Feb 5–8, in San Antonio, Tex.

The study analyzed the results of surgeries for 105 patients conducted at The James between March 2006 and April 2008 using the da Vinci robot, compared to 76 patients who received minimally invasive laparoscopic surgery for endometrial cancer, said principal investigator Jeffrey M. Fowler, MD, director of the Division of Gynecologic Oncology and chief of staff at The James.

Benefits of Robotic Approach
“Our study found that robotic hysterectomy and lymph node removal for uterine cancer results in shorter hospital stays and faster overall recovery with fewer complications compared with laparoscopic surgery,” said Dr. Fowler, who also is a researcher at Ohio State’s Comprehensive Cancer Center. “While this is still a major surgery, robotassisted minimally invasive methods can greatly reduce blood loss, pain and scarring, and risk of infection. We can now also use the technology in heavier patients.”

He continued, “Typically, patients with uterine cancer tend to be overweight or obese with high blood pressure and diabetes, and therefore are at greater risk for postsurgical complications, especially wound healing. Our study showed that overweight or obese patients can benefit most from this approach.”

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
Related Content